IDXX
IDEXX Laboratories·NASDAQ
--
--(--)
--
--(--)
IDXX fundamentals
IDEXX Laboratories (IDXX) released its earnings on Feb 2, 2026: revenue was 1.09B (YoY +14.28%), beat estimates; EPS was 3.08 (YoY +17.56%), beat estimates.
Revenue / YoY
1.09B
+14.28%
EPS / YoY
3.08
+17.56%
Report date
Feb 2, 2026
IDXX Earnings Call Summary for Q4,2025
- Revenue & Profit Growth: Q4 2025 EPS of $3.08 (17% YoY), full-year EPS of $13.08 (14% YoY). 2026 revenue guidance of $4.632B-$4.720B reflects 7.6%-9.6% growth.
- Innovation Drives Growth: 6,400 inVue Dx placements in 2025, Cancer Dx screening in 50% of lymphoma cases. FNA on inVue Dx to launch Q1 2026.
- Software Expansion: Vello users grew 40% QoQ, with clinics seeing higher visit frequency and diagnostic compliance.
- Commercial Momentum: 2026 inVue Dx placements target 5,500, with FNA expected to add $130M annually in North America.
- Margin Expansion: 2026 operating margin target of 32.0%-32.5%, supported by gross margin gains and controlled expense growth.
EPS
Actual | 1.29 | 1.72 | 1.69 | 2.01 | 2.35 | 2.34 | 2.03 | 1.89 | 2.27 | 1.56 | 2.15 | 2.05 | 2.55 | 2.67 | 2.53 | 2.32 | 2.81 | 2.44 | 2.8 | 2.62 | 2.96 | 3.63 | 3.4 | 3.08 | |||||||||||||
Forecast | 1.201 | 1.1704 | 1.4314 | 1.3975 | 1.713 | 2.0271 | 1.9147 | 1.7184 | 2.2478 | 1.562 | 2.0501 | 1.9237 | 2.4217 | 2.4744 | 2.3708 | 2.1241 | 2.7124 | 2.8846 | 2.6805 | 2.4028 | 2.8481 | 3.3022 | 3.138 | 2.9332 | |||||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +7.41% | +46.96% | +18.07% | +43.83% | +37.19% | +15.44% | +6.02% | +9.99% | +0.99% | -0.13% | +4.87% | +6.57% | +5.30% | +7.90% | +6.72% | +9.22% | +3.60% | -15.41% | +4.46% | +9.04% | +3.93% | +9.93% | +8.35% | +5.00% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 626.34M | 637.59M | 721.79M | 720.94M | 777.71M | 826.14M | 810.42M | 801.09M | 836.55M | 860.55M | 841.66M | 828.57M | 900.20M | 943.63M | 915.53M | 901.60M | 964.10M | 1.00B | 975.54M | 954.29M | 998.43M | 1.11B | 1.11B | 1.09B |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 617.42M | 593.05M | 672.48M | 681.03M | 738.43M | 788.86M | 797.61M | 781.83M | 837.10M | 863.14M | 830.00M | 820.91M | 890.68M | 934.59M | 926.88M | 891.88M | 964.41M | 1.01B | 980.32M | 935.15M | 997.10M | 1.07B | 1.07B | 1.07B |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +1.44% | +7.51% | +7.33% | +5.86% | +5.32% | +4.73% | +1.61% | +2.46% | -0.07% | -0.30% | +1.40% | +0.93% | +1.07% | +0.97% | -1.23% | +1.09% | -0.03% | -0.31% | -0.49% | +2.05% | +0.13% | +4.00% | +2.98% | +1.67% |
Earnings Call
You can ask Aime
What is the revenue and EPS growth rate for IDEXX Laboratories year over year?What is IDEXX Laboratories's gross profit margin?What guidance did IDEXX Laboratories's management provide for the next earnings period?Did IDEXX Laboratories beat or miss consensus estimates last quarter?What is IDEXX Laboratories's latest dividend and current dividend yield?What were the key takeaways from IDEXX Laboratories's earnings call?What does IDEXX Laboratories do and what are its main business segments?What were the key takeaways from IDEXX Laboratories’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
